Trial Profile
A Multicenter, Phase II, Open Label, Randomized Trial Evaluating the Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Nivolumab (Primary) ; OSE 2101 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms COMBI-TED
- 19 Jan 2024 According to an OSE Immunotherapeutics media release, results from this study expected in 2025.
- 15 Sep 2023 Planned primary completion date changed from 17 May 2023 to 17 Oct 2023.
- 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology